BIOMAT Database Logo BIOMAT Database Logo

Relationship between elevation in the plasma concentration of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and haemostatic parameters during haemodialysis. 1995

M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.

To investigate the relationship between changes in plasma concentrations of polymorphonuclear elastase (PMN-E) and haemostatic effects during haemodialysis (HD), changes in the plasma concentrations of elastase-alpha 1 proteinase inhibitor complex (E-alpha 1 PI) and fibrinogen (Fbg), cross-linked fibrin degradation products (XDP), thrombin-antithrombin III complex (TAT), plasmin-alpha 2 plasmin inhibitor complex (PIC) and soluble thrombomodulin (TM) in 49 patients with end-stage chronic glomerulonephritis maintained on chronic HD were measured. Plasma concentrations of TAT, PIC, TM and E-alpha 1 PI significantly increased during a single HD. There was a statistically significant correlation between change in plasma E-alpha 1 PI concentration and changes in plasma concentrations of TAT, PIC and TM during a single HD, as well as between changes in plasma concentrations of TM and TAT during a single HD. These observations suggested that activation of coagulation and fibrinolysis, endothelial cell damage, and activation of polymorphonuclear cells occur during HD. Activation of polymorphonuclear cells may induce activation of coagulation and fibrinolysis, leading to endothelial cell damage, augmented by release of proteases such as elastase.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses

Related Publications

M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Plasma levels of human granulocytic elastase alpha 1-proteinase inhibitor complex (E-alpha 1-PI) in leukemia.
May 1984, Blut,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
[Elastase-alpha 1-proteinase inhibitor complex (E alpha 1 PI) and lactoferrin plasma concentrations in viral and bacterial infections].
February 1991, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Quantitative estimation of elastase-alpha 1-proteinase inhibitor (E-alpha 1 PI) complex in leukemia: marked elevation in cases of acute promyelocytic leukemia.
January 1989, Thrombosis research,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
[Plasma elastase alpha 1-proteinase inhibitor complex in children with bronchitis].
September 1996, Pediatria polska,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
[Plasma concentration of polymorphonuclear leukocyte elastase-alpha 1-proteinase inhibitor complex in patients with gastric ulcer].
August 1990, Rinsho byori. The Japanese journal of clinical pathology,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Conformational stability of the covalent complex between elastase and alpha 1-proteinase inhibitor.
February 1991, Archives of biochemistry and biophysics,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome.
February 1994, The European respiratory journal,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Plasma polymorphonuclear leukocyte elastase-alpha 1-proteinase inhibitor complex in patients with gastric ulcer.
August 1990, Clinica chimica acta; international journal of clinical chemistry,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Elevation of plasma truncated elastase alpha 1-proteinase inhibitor complexes in patients with inflammatory lung diseases.
July 1992, Chest,
M Yamazaki, and H Asakura, and M Saito, and H Jokaji, and C Uotani, and I Kumabashiri, and E Morishita, and K Aoshima, and T Sato, and Y Tsugawa
Elastase-alpha 1 proteinase inhibitor assay.
February 1991, Annals of the rheumatic diseases,
Copied contents to your clipboard!